(Q46274957)

21 December 2017

title

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database (English)

1 reference

21 December 2017

4

Ulf Müller-Ladner

1 reference

21 December 2017

0 references

Britta Maurer

1

1 reference

21 December 2017

Nicole Graf

2

1 reference

21 December 2017

Beat A Michel

3

1 reference

21 December 2017

László Czirják

5

1 reference

21 December 2017

Christopher P Denton

6

1 reference

21 December 2017

Alan Tyndall

7

1 reference

21 December 2017

Carola Metzig

8

1 reference

21 December 2017

Vivian Lanius

9

1 reference

21 December 2017

Dinesh Khanna

10

1 reference

21 December 2017

Oliver Distler

11

1 reference

21 December 2017

EUSTAR co-authors

12

1 reference

21 December 2017

language of work or name

English

0 references

publication date

30 June 2014

1 reference

21 December 2017

Annals of the Rheumatic Diseases

published in

1 reference

21 December 2017

volume

74

1 reference

21 December 2017

issue

6

1 reference

21 December 2017

page(s)

1124-1131

1 reference

21 December 2017

Evidence-based management of rapidly progressing systemic sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Registries in systemic sclerosis: a worldwide experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Assessing the performance of prediction models: a framework for traditional and novel measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205226

10.1136/ANNRHEUMDIS-2014-205226

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

PubMed ID

24981642

1 reference

21 December 2017